INTRODUCTION {#sec1-1}
============

Neuroanaesthesiology is a rapidly growing and evolving branch of medicine, which not only has evolved as a separate super-specialty, but has also witnessed remarkable achievements in neuroanesthetic techniques. All this may be accredited to better understanding of pathophysiological processes, advent of newer state of the art neuromonitoring techniques and high quality research carried out in various aspects of neuroanaesthesiology and neurocritical care. Despite all developments, controversies still exist. Majority of recently conducted multicentric trials provide equivocal results with little clinical significance.

In this review we discuss the strength and weakness of landmark studies, published between 2007 and 2012, on controversial topics in neuroanaesthesia along with a brief review of how their results influence our current practice or thinking.

An extensive literature search was performed through MEDLINE, PubMed, Google Scholar, science journals and textbooks to identify such studies using key words "neuroanaesthesiology," "traumatic brain injury," "aneurysmal subarachnoid haemorrhage," "carotid artery disease," "brain protection," "glycemic management" and "neurocritical care."

TRAUMATIC BRAIN INJURY {#sec1-2}
======================

Fluid resuscitation {#sec2-1}
-------------------

In patients with severe traumatic brain injury (TBI), aggressive fluid resuscitation is of utmost importance to prevent hypotension, subsequent mortality and secondary neurological injury.\[[@ref1][@ref2]\] The American guidelines for pre-hospital management of TBI advocates avoidance of hypotension (systolic blood pressure \<90 mmHg in adults).\[[@ref2]\] However, the ideal resuscitation fluid has always been a matter of debate -- isotonic versus hypertonic fluids and colloid versus crystalloid.

### Hypertonic saline versus normal saline {#sec3-1}

Currently, initial fluid resuscitation in traumatic patients begins in out-of-hospital settings and, despite lack of evidence, is considered standard of care. The major reason for pre-hospital hypotension after TBI is hypovolemia from blood loss and requires blood transfusion ideally. In its absence, isotonic fluid resuscitation is recommended;\[[@ref2]\] however, the relatively large volumes of fluid required may exacerbate cerebral oedema. In comparison, hypertonic solutions (1.6% to 23.4% saline), either alone or combined with dextran, have potential of early restoration of intravascular volume with a smaller fluid volume,\[[@ref3]\] improved cerebral perfusion with reduced intracranial pressure (ICP)\[[@ref4]\] and a possible modulation of the inflammatory response.\[[@ref5][@ref6]\]

To determine whether an early out-of-hospital administration of hypertonic fluids would be able to improve long-term neurologic outcome, Bulger *et al*. conducted a multicentric randomized controlled trial (RCT) of fluid resuscitation among 1282 patients with severe TBI \[Glasgow coma scale (GCS) score \<8\] without hypovolemia.\[[@ref7]\] Patients were randomly distributed to receive a single 250 ml bolus of either 0.9% saline (NS), 7.5% hypertonic saline (HS) or HS/6% dextran-70 combination for initial fluid resuscitation. Authors observed that, compared with NS, HS resuscitation offered no benefit in terms of survival (74.3% with HS/dextran, 75.7% with HS and 75.1% with NS, *P*=0.88) or better neurological outcome. However, the lack of effect of hypertonic resuscitation was attributed to varied treatment protocols, dilutional effects of crystalloids and a short period of hyperosmolarity. Authors concluded that their study results does not preclude a benefit from HS as it was administered differently but, at present there appears to be no compelling reason to adopt a practice of hypertonic fluid resuscitation in patients with TBI in the out-of-hospital setting. Notably in this study, patients with the most fatal prognosis, ones with hemorrhagic shock, were excluded.

Thus, current data do not support routine use of hypertonic fluid resuscitation in TBI patients. HS, however, may be considered as a treatment option in patients with severe TBI.\[[@ref2]\]

### Colloid versus crystalloid {#sec3-2}

Saline versus Albumin Fluid Evaluation (SAFE) study was the first large multicentric RCT of albumin versus NS fluid resuscitation in 6,997 patients admitted in multidisciplinary intensive care units (ICUs) and showed no difference in 28-day mortality. In post-hoc analysis of SAFE study subgroup with TBI (*n*=460), severe TBI patients treated with albumin had a 1.88 fold increased relative risk (RR) of death at 24 months compared with saline treated subjects (*P*\<0.001), possibly because of exacerbation of cerebral edema by albumin.\[[@ref8]\] Results of this study led to the recent recommendation by European Society of Intensive Care Medicine that colloids should not be used in patients with TBI.\[[@ref9]\]

On-going Crystalloid versus Hydroxyethyl Starch Trial (CHEST trial) comparing NS fluid resuscitation with third generation hydroxyethyl starch 130/0.4 in 7000 ICU patients, including mild to moderate TBI patients, is expected to further clear the controversy of colloid versus crystalloid resuscitation in the critically ill.\[[@ref10]\]

Targeted approach for optimal cerebral perfusion pressure {#sec2-2}
---------------------------------------------------------

The optimal management strategy for treatment of increased ICP has traditionally been either *cerebral perfusion pressure* *(CPP)* *targeted* (Rosner\'s concept) which advocates increasing blood pressure to augment cerebral blood flow (CBF) and CPP\[[@ref11]\] or ICP targeted which focuses on aggressive reduction of *ICP* as the primary target.\[[@ref12]\] A specific and more common subcategory of ICP control involves a "*volume-targeted*" strategy (Lund\'s concept) based on physiological principles for brain volume regulation and improved microcirculation.\[[@ref13]\] Both concepts have their own merits and demerits. However, in absence of well-controlled randomized comparative studies, no approach can be stated superior to other.

With the advent of advanced multimodal neuromonitoring, a more individualized and patient-specific approach for optimal CPP appears promising. Over years, there has been a paradigm shift in neuromonitoring in TBI patients-from global ICP and CPP monitoring to more localized brain tissue oxygen (PbtO~2~) monitoring. Studies have been published from advanced neurosurgical centers comparing PbtO~2~ based therapy with ICP/CPP based therapy in TBI.\[[@ref14][@ref15]\] However, as yet, there is no strong outcome evidence to support this approach likewise. Until further research, the current brain trauma foundation (BTF) guidelines of maintaining CPP within 50-70 mmHg (level III evidence) and ICP \<20 mmHg (level II evidence) continues to be the gold standard treatment target.\[[@ref16]\]

Tranexamic acid in TBI {#sec2-3}
----------------------

Antifibrinolytics reduce blood loss in patients undergoing surgery by inhibiting fibrinolysis and, hence, improve hemostasis. Clinical Randomization of an Antifibrinolytic in Significant Head Injury (CRASH-2 trial) evaluated the effect of tranexamic acid (TXA) in bleeding traumatic patients and found that an early administration within eight hours of injury is safe and effective in reducing all-cause mortality compared to placebo (RR=0.91, *P*=0.0035). As a consequence of trial results, TXA has been incorporated into trauma treatment protocols worldwide and has been included on the World Health Organization List of Essential Medicines.

To quantify the effect of TXA on intracranial haemorrhage, the CRASH-2 Intracranial Bleeding Study evaluated 270 adult patients with TBI out of 20,211 trauma patients recruited in the CRASH-2 trial.\[[@ref17]\] There was a reduction in intracranial haemorrhage growth (--3.8 ml, *P*=0.33), ischemic lesions and mortality (11% vs 18%; *P*=0.06) in TXA allocated patients, but these results were statistically insignificant showing neither moderate benefits nor harmful effects of TXA in TBI patients. Results of ongoing CRASH-3 will reliably determine the effectiveness of early administration of TXA in TBI patients.\[[@ref18]\]

Decompressive craniectomy in patients with resistant intracranial hypertension {#sec2-4}
------------------------------------------------------------------------------

In a review of therapies for treatment of intracranial hypertension (ICH), Schreckinger *et al*., reported decompressive craniectomy (DC) as most effective method than mannitol, cerebrospinal fluid drainage, HS, hyperventilation, barbiturates or hypothermia.\[[@ref19]\] DC, however, is also associated with serious medical complications, intracranial infection and a need for later cranioplasty.

In Decompressive Craniectomy in Diffuse Traumatic Brain Injury (DECRA) trial, early bifrontotemporoparietal DC was found to decrease ICP (14.4 mmHg vs. 19.1 mmHg, *P*\<0.001) and the length of stay in ICU (13 vs. 18, *P*\<0.001) but was associated with more unfavorable functional outcomes.\[[@ref20]\] Fifty-one patients (70%) who underwent DC either died, were in a vegetative state or had severe disabilities 6 months after injury, compared with only 42 patients (51%) in the standard-care group (*P*=0.02).

This study has been criticized for the bias created by allowing compassionate use of DC in the standard-care group if, after 72 h, ICP could not otherwise be controlled. The currently on-going Randomized Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intra-Cranial Pressure (RESCUEicp study) will further determine the role of DC in managing resistant ICH.\[[@ref21]\]

Osmotherapy: Mannitol versus hypertonic saline {#sec2-5}
----------------------------------------------

Hyperosmolar therapy remains the primary medical management strategy for ICH. Till now, mannitol has been considered as the gold standard hyperosmolar agent. However, HS has become a progressively more common alternative to mannitol, with current literature proving its relative superiority.

Patients with TBI and stroke {#sec2-6}
----------------------------

When used in stable patients of TBI and stroke with ICH and intact cerebral autoregulation, single equiosmolar doses of 20% mannitol and 7.45% HS were found to exhibit comparable effectiveness in reducing ICP.\[[@ref22]\] Investigators were of the opinion that factors such as serum sodium, systemic and brain haemodynamics should be considered while choosing the most appropriate osmotic compound.

During elective craniotomy {#sec2-7}
--------------------------

Equiosmolar solutions of 20% mannitol and 3% HS in patients undergoing craniotomy were found to be associated with similar brain relaxation scores and cerebral arterio-venous oxygen and lactate difference.\[[@ref23]\] Rozet *et al*. hence recommended HS as a safe alternative to mannitol for intraoperative brain debulking, especially in haemodynamically unstable patients. Results of recently published meta-analysis of RCT suggest HS to be comparatively effective than mannitol for the treatment of elevated ICP regardless of the concentration used, mode of administration (bolus or continuous drip) or origin of ICH.\[[@ref4]\]

Thus, mannitol can be used as first-line agent in patients with evidence of pretreatment brain hypoperfusion, whereas HS can be recommended to treat patients with pretreatment hypovolemia or hyponatremia.

BRAIN PROTECTION {#sec1-3}
================

Mild to moderate therapeutic hypothermia represents one of the most solidly evidence-based neuroprotective strategies currently available. Despite successful results in experimental studies, by far no anesthetic or non-anesthetic pharmacological agent has been convincingly shown to provide profound neuroprotection in humans.

Hypothermia in TBI {#sec2-8}
------------------

National Acute Brain Injury Study: Hypothermia II trial (NABIS: H-II) does not confirm the utility of hypothermia as a primary neuroprotective strategy in patients with severe TBI.\[[@ref24]\] However, subgroup analysis suggests that patients who underwent surgical removal of intracranial hematomas and had hypothermia had significantly fewer poor outcomes than patients who had normothermia (*P*=0.02), whereas in patients with diffuse injury, there was a trend toward worse outcomes with hypothermia (*P*=0.09). Hypothermia, therefore, warrants further evaluation to confirm benefit in specific TBI subgroups.

The Prophylactic Hypothermia to Lessen TBI (POLAR-RCT) trial and The Eurotherm-3235 trial are presently underway to assess the efficacy of therapeutic hypothermia in TBI. Pending their results, BTF guidelines provide level III evidence that prophylactic hypothermia is not significantly associated with decreased mortality.\[[@ref16]\] Current recommendations are that therapeutic hypothermia should not be considered as standard of care for patients with severe TBI but may be beneficial when used by experienced clinicians within few hours after TBI for more than 48 hours (Class IIA evidence).\[[@ref25]\]

Hypothermia during aneurysmal subarachnoid haemorrhage surgery {#sec2-9}
--------------------------------------------------------------

After landmark IHAST trial, refuting the benefits of intraoperative hypothermia (target temperature, 33.0°C) as an effective neuroprotective modality among good-grade patients with aneurysmal subarachnoid haemorrhage (SAH),\[[@ref26][@ref27]\] no large study has yet been carried out for evaluating the efficacy of hypothermia in preventing postoperative neurological deficits. Based on clinical data, mild hypothermia may still have beneficial effects in patients with good-grade SAH.\[[@ref28]\] The latest American Heart Association (AHA)/American Stroke Association (ASA) guidelines for management of aneurysmal SAH recommend induced hypothermia as a reasonable option in selected cases only \[Class III, Level of Evidence (LOE)-B\].\[[@ref29]\]

Use of intravenous inducing agents {#sec2-10}
----------------------------------

In post-hoc analysis of IHAST data, administration of thiopental or etomidate was not found to have any clinically demonstrable effect on postoperative neurologic outcomes in patients undergoing temporary clipping.\[[@ref30]\] According to AHA/ASA guidelines for management of aneurysmal SAH, at present there is insufficient data to recommend their routine use, apart from a few selected cases such as those with high risk of prolonged temporary clipping (Class IIb, *LOE*-C).\[[@ref29]\]

Primary treatment modality of aneurysmal subarachnoid haemorrhage {#sec2-11}
-----------------------------------------------------------------

The International Subarachnoid Aneurysm Trial (ISAT) is the largest trial till date comparing clipping and coiling of ruptured intracranial aneurysms. Higher independent survival rate was observed in patients with small anterior circulation aneurysms of good neurological grade who underwent endovascular coiling than those undergoing neurosurgical clipping. Long-term follow up revealed an increased small risk of recurrent bleeding from coiled aneurysm compared with clipped aneurysm\[[@ref31]\] and a greater incidence of clinically defined delayed cerebral ischemia (DCI) after neurosurgical clipping than after endovascular coiling.\[[@ref32]\]

Results of ISAT have largely changed the management of intracranial aneurysms worldwide. Neuroanesthesiologists now face the challenge of managing critically ill aneurysmal SAH patients in the remote locations of neuroradiological suite more often. ISAT remains the most influential study in neurosurgery and, at the same time, the most controversial and criticized one for the recruitment biases and operators' selection. In the multicentric Clarity GDC study, all patients of ruptured intracranial aneurysm underwent coiling as first-intention treatment by non-selected operators and the results were still very similar to ISAT.\[[@ref33]\]

Current AHA/ASA guidelines recommend endovascular coiling in patients with ruptured aneurysms, which are judged technically amenable to both treatment modalities (Class I; *LOE*-B).\[[@ref29]\]

ANAESTHESIA FOR NEUROSURGICAL PROCEDURES {#sec1-4}
========================================

General anaesthesia versus local anaesthesia {#sec2-12}
--------------------------------------------

The General Anaesthesia versus Local Anaesthesia (GALA) for Carotid Surgery trial examined the use of general anaesthesia (GA) versus local anaesthesia (LA) in 3500 patients undergoing carotid endarterectomy (CEA) and found no significant difference between the two groups with regard to length of hospital stay, quality of life and major perioperative complications.\[[@ref34]\] Investigators suggested that there is no reason to prefer one technique over another as routine and choice should be made on an individual basis. Similar conclusion was drawn in the Cochrane review of LA versus GA for CEA.\[[@ref35]\] However, in a subgroup analysis of GALA study, performing CEA under LA was associated with significantly lower serum levels of neuro-biochemical marker of cerebral ischemia (S100ß; 0.06 μg/l vs. 0.087 μg/l, *P*=0.006) and better performance in neurocognitive tests.\[[@ref36]\] Consequently, it appears that LA should be preferred over GA for better neurocognitive outcome if both techniques are feasible.

NEURO-MONITORING {#sec1-5}
================

During carotid endarterectomy {#sec2-13}
-----------------------------

Moritz *et al*. did a comparison of transcranial Doppler (TCD), near-infrared spectroscopy (NIRS), stump pressure (SP) measurement and somatosensory evoked potentials (SSEP) in patients undergoing CEA during regional anaesthesia to determine their accuracy in detecting cerebral ischemia.\[[@ref37]\] Although TCD, NIRS and SP measurement provided equal sensitivity and specificity, TCD monitoring was least practical of all. Authors suggested use of SP or NIRS for detection of cerebral ischemia during carotid artery surgery. However, under GA, NIRS proved better than SP measurement as indicator for shunting during CEA.\[[@ref38]\]

Electrophysiological monitoring during spine surgery {#sec2-14}
----------------------------------------------------

Multimodality intraoperative monitoring of spinal cord sensory and motor function during surgical correction of adult spinal deformity is feasible and provides useful neurophysiological data with an overall sensitivity of 100% and a specificity of 84.3%.\[[@ref39]\] Similarly, combined neurophysiological monitoring with electromyography and SSEP recording, and the selective use of motor evoked potential was found to be helpful for predicting and possibly preventing neurological injury during cervical spine surgery.\[[@ref40]\]

Hyperventilation versus normoventilation during anaesthesia for supratentorial craniotomy {#sec2-15}
-----------------------------------------------------------------------------------------

In the multicentric randomized crossover trial of hyperventilation and normoventilation in patients undergoing craniotomy for supratentorial brain tumors by Gelb *et al*., intraoperative hyperventilation (PaCO~2~ 25 vs 37 mmHg) was found to be associated with reduced ICP (12 vs 16 mmHg, *P*\<0.001) and 45% reduction (*P*=0.004) in surgeon-assessed brain bulk, independent of anesthetic used. The study results thus support the use of intraoperative hyperventilation as part of the neuroanesthetic technique.\[[@ref41]\]

Use of nitrous oxide in anesthetic gas mixture {#sec2-16}
----------------------------------------------

Controversy regarding nitrous oxide use in the general neurosurgical population exists despite its successful use for over 160 years. The initial results of Evaluation of Nitrous Oxide in the Gas Mixture for Anaesthesia (ENIGMA trial) led to questioning of the routine use of nitrous oxide in adult patients undergoing major surgery.\[[@ref42]\] Myles *et al*. showed that in 2,050 patients undergoing non-cardiac surgery, avoidance of intraoperative nitrous oxide combined with supplementary oxygen decreases the incidence of major complications \[odds ratio (OR) =0.71, *P*=0.003\] and severe nausea and vomiting (OR=0.40, *P*\<0.001) but does not significantly affect duration of hospital stay (7.0 vs. 7.1 days, *P*=0.06). On long-term follow up, increased risk of myocardial infarction (adjusted OR=1.59, *P*=0.04) was observed in patients exposed to nitrous oxide, but not of death or stroke.\[[@ref43]\] This trial included 295 neurosurgical patients but did not provide specific information about them.

Till date, only two investigations have evaluated the effect of nitrous oxide on outcome in humans at risk for cerebral ischemia. When analyzing the entire IHAST population, nitrous oxide use was found benign with no consistent effect on development of postoperative delayed ischemic neurologic deficit (DIND) and long-term gross neurological outcome.\[[@ref44]\] However, in subset of patients who underwent temporary clipping and were thus likely to experience intraoperative cerebral ischemia, nitrous oxide use was found to be associated with an increased risk of developing DIND, but again with no evidence of detriment to neurologic outcome.\[[@ref45]\]

A recent subgroup analysis of GALA trial patients given GA provides evidence that nitrous oxide use does not increase the risk of mortality, stroke and myocardial infarction.\[[@ref46]\] However, the trial was underpowered to detect any difference between two groups and the authors emphasize the need for conducting future trials in patients who are vulnerable to nitrous oxide, like those who are malnourished or deficient in cobalamin or folate. Thus, apart from avoiding nitrous oxide in such vulnerable patients, in presence of pneumocephalus and during acute venous air embolism, there is at present no logical rationale to avoid nitrous oxide in neurosurgical patients.

ANESTHETIC TECHNIQUES {#sec1-6}
=====================

An ideal neuroanesthetic technique provides optimal intracranial operating conditions, maintains cerebral haemodynamics to ensure adequate cerebral perfusion, provides some amount of neuroprotection and allows rapid recovery.

In a multicentric RCT comparing emergence after sevoflurane/remifentanil anaesthesia with propofol/remifentanil anaesthesia for supratentorial craniotomy (Gas Anaesthesia versus Intravenous Anaesthesia-GAIA Trial), Lauta *et al*. found no difference in the two anesthetic techniques in terms of time to reach adequate recovery.\[[@ref47]\] Authors suggested that patient age and anesthetic duration seem to influence anesthetic emergence more than the choice of sevoflurane over propofol.

Recently, use of desflurane and dexmedetomidine has also been evaluated in neurosurgical patients in many single centre studies. Clinical efficacy and safety profile have promoted their inclusion in current neuroanaesthesiology drug armamentarium.\[[@ref48][@ref49][@ref50][@ref51]\]

Glycemic control of neurosurgical patients {#sec2-17}
------------------------------------------

Both hyperglycemia as well as hypoglycemia have detrimental effects on brain with or at risk of ischemia. Pooled evidence from various studies\[[@ref52]\] and a recently conducted multicentric Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR study) in adult ICU patients suggest that tight glycemic control \[blood glucose concentration (BGC) -- target range 80-110 mg/dl\] increases the risk of hypoglycemia as compared to conventional therapy (with BGC -- 180 mg/dl or less).\[[@ref53]\] On the other hand, hyperglycemia (mean BGC \>140 mg/dl or even a single episode of BGC \>200 mg/dl) is known to be associated with worsened neurological outcome.\[[@ref54]\]

Post-hoc analysis of IHAST data has shown that intraoperative hyperglycemia was associated with long-term changes in gross neurologic function in neurosurgical patients at risk for new onset intraoperative and postoperative cerebral ischemia.\[[@ref55]\] Authors thus advocated rigid glucose control in patients with aneurysmal SAH who undergo clipping.

In a prospective RCT of intensive insulin therapy (IIT) compared with conventional therapy (BGC target \<215 mg/dl) in 483 patients undergoing elective or emergency brain surgery, IIT resulted in increased risk of iatrogenic hypoglycemia (*P*\<0.0001), but also reduced the infection rate (25.7% vs. 39.3%; *P*=0.0018) and shortened the ICU stay (6 vs. 8 days; *P*=0.0001).\[[@ref56]\] Green *et al*. found no benefit of IIT over conventional treatment on functional outcome in critically ill stroke and TBI patients.\[[@ref57]\] Authors suggested that IIT for glucose control cannot be recommended in critically ill neurological patients.

In a recent cerebral microdialysis study, Magnoni *et al*. demonstrated that linear relationship between systemic glucose and brain glucose is preserved in patients with TBI and identical blood glucose levels translate into lower cerebral glucose availability when cerebral oxidative metabolism was disturbed.\[[@ref58]\] Hence, brain glucose in tissues with disturbed oxidative metabolism may decrease to dangerously low levels even with systemic glucose being in the lower limit of "normal range". Authors thus propose a new concept of improved tolerance towards hyperglycemia in patients with severe TBI and strongly recommend avoiding severe glycemic reductions.

Presently, the best practice seems to adopt a moderate range of target BGC 140-180 mg/dl. AHA/ASA guidelines also recommend avoiding intraoperative hyperglycemia (Class IIa, *LOE*-B), minimizing glucose variability and aggressive management of hypoglycemia (Class IIb, *LOE*-B).\[[@ref29]\]

INTENSIVE CARE MANAGEMENT ON NEUROSURGICAL PATIENTS {#sec1-7}
===================================================

Management of cerebral vasospasm after aneurysmal SAH {#sec2-18}
-----------------------------------------------------

At present, many treatment options are available for preventing and treating cerebral vasospasm following aneurysmal SAH. However, only nimodipine has shown beneficial results till now (Class I; *LOE*-A).\[[@ref29]\] Triple-H therapy, fasudil, transluminal balloon angioplasty, thrombolytics, endothelin receptor antagonists, magnesium, statins and miscellaneous therapies such as free radical scavengers and antifibrinolytics require further evaluation.\[[@ref29][@ref59]\]

### Triple-H therapy {#sec3-3}

Several studies have described the effectiveness of triple-H therapy for preventing neurologic deficits due to cerebral vasospasm. However, it was unclear which components of the triple-H therapy are crucial for the treatment of cerebral hypoperfusion.

Muench *et al*. first performed an experimental study in five healthy porcine models and later applied the same protocol in ten patients with aneurysmal SAH to investigate the efficacy of catecholamine-induced arterial hypertension, hypervolemia/hemodilution and hypervolemic arterial hypertension on ICP, regional cerebral blood flow (rCBF) and PbtO~2~.\[[@ref60]\] In animals with intact autoregulation, neither induced hypertension nor hypervolemia had an effect on ICP, PbtO~2~ or rCBF. However, in patients with SAH, triple-H therapy failed to improve rCBF more than hypertension alone (mean arterial pressure 143±10 mmHg) and was characterized by the drawback that the hypervolemia and hemodilution component reversed the effect of induced hypertension on PbtO~2~.

A systematic review of studies exploring the effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal SAH also concluded that although there is no good evidence in support of triple-H therapy or its individual components on increasing CBF in SAH patients, hypertension still seems to be more effective than either hypervolemia or hemodilution.\[[@ref61]\]

Based on clinical data, AHA/ASA guidelines recommend maintaining euvolemia and normal circulating blood volume to prevent DCI and induced hypertension for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it (Class I, LOE-B).\[[@ref29]\]

### Stellate ganglion block {#sec3-4}

Stellate ganglion block (SGB) has an established role in treating patients with sympathetic pain syndromes like post-herpetic neuralgia. With respect to its cerebral circulatory effects, SGB has been found to decrease cerebral vascular tone and hence cause a significant increase in CPP.\[[@ref62]\] In a preliminary study by Jain *et al*. in 15 patients who underwent aneurysmal clipping and developed refractory cerebral vasospasm, SGB was found to be an effective treatment modality with reduced ipsilateral middle cerebral artery mean flow velocity (from 133.66 cm/s to 110.53 cm/s at 6 h and 121.62 cm/s at 24 h, *P*\<0.001) and improved GCS.\[[@ref63]\] Overall, neurological deficits improved in 11 patients.\[[@ref56]\] Authors suggested that this promising therapeutic modality needs to be evaluated further in a large RCT as a single mode of therapy by comparing its efficacy with other treatment modalities for cerebral vasospasm.

Sedation of neurocritical care patients {#sec2-19}
---------------------------------------

Dexmedetomidine-based sedation (either alone or as an adjunct to propofol infusion) has been safely used for both intubated and extubated neurocritical care patients. However, patients may require higher doses and prolonged duration of infusions to achieve desired levels of sedation with clinically insignificant haemodynamic effects. Bolus loading may be avoided to prevent potential adverse effects.\[[@ref64][@ref65]\]

CONCLUSION {#sec1-8}
==========

In the era of rapidly evolving science, it is imperative to keep ourselves abreast of the on-going research work and improvise our practice based on evidence-based results. Recent research in TBI patients favors HS for osmotherapy but not for pre-hospital fluid resuscitation. Colloids are no more recommended and the role of multimodality monitoring, therapeutic hypothermia, TXA and DC in this patient population needs further evaluation. For patients with aneurysmal SAH, there is sound evidence to prefer endovascular coiling over aneurysmal clipping, while routine use of intraoperative hypothermia and anesthetics as clinical effective neuroprotectants is not recommended. During CEA, loco-regional anaesthesia appears favorable over GA. Intraoperative hyperventilation has been accepted as a part of neuroanesthetic technique during elective craniotomies and use of nitrous oxide is no more condemned. IIT has given way to more liberal target blood glucose levels, stressing on avoidance of hypoglycemia. Therapeutic strategies for prevention and treatment of cerebral vasospasm need further evaluation. Role of SGB in managing resistant cerebral vasospasm appears promising in future. Lessons from the many recent failed trials have led to an improved methodology of the currently on-going clinical trials and their results are expected to bring a breakthrough in modern neuroanaesthesiology practice.
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